Uses of Ckdmyrept

Ckdmyrept medicine contains the main ingredient is Mycophenolate mofetil 500mg, in the form of film-coated tablets. The drug is used to prevent acute rejection, poor response or first-time rejection in liver transplant recipients. The necessary information of Ckdmyrept drug on ingredients, uses, doses and side effects will help improve treatment results for patients.

The Mycophenolate mofetil ingredient in Ckdmyrept is an ester of mycophenolic acid (MPA). After entering the patient's body, Mycophenolate mofetil will be converted to MPA which is an active substance. The mechanism of action of MPA is to inhibit the enzyme Inosine monophosphate Dehydrogenase (IMPDH), which prevents the catalysis of IMPDH to convert IMP to xanthose-5'-monophosphate.
This is considered a major step in the denovo pathway of Guanosine nucleotide synthesis. The IMPDH inhibitory effects of Mycophenolate mofetil are potent, selective, and reversible. MPA has a stronger inhibitory effect on B and T lymphocytes than other cells because lymphocytes are highly dependent on the Denovo pathway for Guanosine synthesis while other cells can utilize the regeneration pathways. create another.

Ckdmyrept is indicated in combination with Corticosteroids and Cyclosporine in the prevention of first-time rejection, acute rejection and poor response in patients with liver, kidney or heart transplants of different bloodlines.

The drug Ckdmyrept is contraindicated in the following cases:
People who are allergic to any ingredient of Ckdmyrept. Women who are breastfeeding.

Usage: The drug Ckdmyrept is taken orally. Patients should take Ckdmyrept with a full glass of water. Chewing, crushing, or breaking Ckdmyrept may make the treatment less effective.
Dosage:
In the prevention of kidney transplant rejection:
For adults: 1g/time x 2 times/day. Patients should take Ckdmyrept within 72 hours of a kidney transplant. For children from 2 to 18 years old: 600 mg/m2 body area/time x 2 times/day. Only use maximum dose of Ckdmyrept 1g / time x 2 times / day for patients with body area > 1.5 m2. For children under 2 years of age: There are no data on safety when using this drug for this subject. For the elderly: 1g dose of Ckdmyrept/time x 2 times/day. In the prevention of heart transplant rejection:
For adults: dose 1.5g/time x 2 times/day. Patients should take Ckdmyrept within 5 days of having a heart transplant. For the elderly: 1.5g dose of Ckdmyrept/time x 2 times/day. In the prevention of liver transplant rejection:
For adults: After a gene transplant, the patient should take Mycophenolate mofetil. On the 4th day, Ckdmyrept was started orally at a dose of 1.5g/time x 2 times/day. For the elderly: dose 1.5g/time x 2 times/day. Note: Ckdmyrept dosage above is for reference only. The specific dose of Ckdmyrept depends on the condition and the progression of the disease. To get the right dose of Ckdmyrept, patients should consult their doctor or healthcare professional.

At therapeutic doses, Ckdmyrept is well tolerated. However, the process of using Ckdmyrept, patients may still experience side effects such as:
Gum hyperplasia; Colitis; Pancreatitis ; Infection ; Agranulocytosis and neutrophils; Aplastic anemia ; Decreased bone marrow. Stop producing red blood cells; Abnormal leukocyte shape. Angioedema ; Anaphylactic reactions; Interstitial lung disease ; Pulmonary fibrosis . If you experience these symptoms, you need to stop using Ckdmyrept and notify your doctor for appropriate treatment.

Ckdmyrept may interact with:
Acyclovir; Antacids; Ganciclovir drug; Tacrolimus drug ; Drug Azathioprine ; Ciprofloxacin medicine ; Amoxicillin drug. To avoid interactions, before being prescribed Ckdmyrept, the patient should inform the doctor about the drugs they are using, including functional foods. The doctor will base on that to prescribe the appropriate Ckdmyrept.

Taking Ckdmyrept may increase your risk of malignancies or lymphomas. Therefore, patients should be careful when using it. It is necessary to monitor the state of bone marrow suppression with manifestations of skin bruising, infection, bleeding in the patient and notify the doctor immediately when there are abnormal signs. Patients will be at risk of opportunistic infections or serious infections when taking Ckdmyrept. In addition, regular blood counts should be checked because Ckdmyrept can cause neutropenia or aplastic erythropoiesis. Store Ckdmyrept in a dry place, the temperature is below 30 degrees Celsius and avoid direct sunlight. Absolutely do not use when the drug Ckdmyrept has signs of discoloration, mold, watery or expired. The article has provided information about the effects of Ckdmyrept, dosage and notes when using it. To ensure safety for your health and maximize the effectiveness of your treatment, you need to take Ckdmyrept exactly as directed by your doctor. Store Ckdmyrept in a dry place, the temperature does not exceed 30 degrees Celsius and out of the reach of small children.